Vulvovaginal candidiasis (VVC) is a common problem in women worldwide, with 75 per cent of women experiencing symptomatic disease at least once throughout their childbearing years. Anti-fungal azoles, including clotrimazole, fluconazole and imidazole administered as topical cream, vaginal pessary or oral tablets remain the standard of care and are effectivein about 70-90% of cases. About 20% of patients fail treatment, i.e remain symptomatic and culture positive following a single standard dose or short course of treatment with anti-fungal azoles. The causes for treatment failure include poor compliance, non-albicans infection or severe disease.

Amphotericin B is a polyene antifungal drug, often used for systemic fungal infections, produced by Streptomyces nodosus. Amphotericin B associates with ergosterol, the main component of fungal cell membranes, forming a transmembrane channel that leads to monovalent ion (K+, Na+, H+ and Cl-) leakage, which is the primary effect leading to fungal cell death. It is broad spectrum Antifungal drug and quite effective against yeasts (Candida albicans, Candida neoformans), endemic mycoses (Histoplasma capsulatum, Blastomyces  dermatitidis and Coccidiodes immitis) and pathogenic molds (Aspergillus  fumigatus and Mucormycosis).

The Amfy® gel (Lipid Based Amphotericin B Gel 0.1%) has been approved by the regulatory authorities for marketing in India. As a part of the extended monitoring efforts to monitor the safety and efficacy of the gel, this post marketing surveillance study is being conducted in the patients of Vulvovaginal candidiasis.